share_log

B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1

B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1

B. Riley Securities將X4製藥評級下調至中性,將目標股價下調至1美元
Benzinga ·  2023/12/12 08:12

B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the price target from $3 to $1.

B. Riley Securities分析師卡爾皮特·帕特爾將X4 Pharmicals(納斯達克股票代碼:XFOR)的評級從買入下調至中性,並將目標股價從3美元下調至1美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論